Colgate-Palmolive (India) Set to Benefit From Some Tailwinds -- Market Talk

Dow Jones
05/25

0310 GMT - Colgate-Palmolive (India) stands to benefit from some tailwinds, Nomura analysts say in a research report. The Indian company's core product portfolio is recovering to normal levels from below-normal levels in FY 2026 and it's doubling down on product premiumization, the analysts note. The oral care products manufacturer's revenue growth momentum is likely to improve and return to near double digits in FY 2027 from flat in FY 2026. Nomura lifts its FY 2027 and FY 2028 EPS estimates for Colgate-Palmolive (India) by around 7% and 10%, respectively. It raises the stock's rating to buy from reduce and the target price to 2,500.00 rupees from 2,050.00 rupees. Shares last closed at 2,157.50 rupees. (ronnie.harui@wsj.com)

 

(END) Dow Jones Newswires

May 24, 2026 23:10 ET (03:10 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10